



Patent Docket P1726R1P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Leonard Presta Serial No.: 09/713,425 Filed: November 15, 2000 For: POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION	Group Art Unit: 1644 Examiner: David Saunders Confirmation No: 3384 CUSTOMER NO: 09157 Express Mail No. EV 351 924 379 US February <u>16</u> , 2005 <u>Anna Kan</u> Anna Kan
---	--

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR § 1.113, or a notice of allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR § 1.17(p) **or** a statement as specified in 37 CFR § 1.97(e), as

checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) **and** a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR § 1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR § 1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR § 1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because **a)** ☐ they were previously cited by or submitted to the Office in a prior application Serial No. 09/483,588, filed January 14, 2000 and relied upon in this application for an earlier filing date under 35 USC § 120 **and/ or** because **b)** ☐ this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003 (**1276 OG 55**). Nevertheless, applicants stand ready to provide

copies at the request of the Examiner.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Date: February 15, 2005

Respectfully submitted,

GENENTECH, INC.

By: Wendy M. Lee

Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1726R1P1

Serial No.

09/713,425

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Presta, L.

Filing Date

15 Nov 2000

Group

1644

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	165	2001/0036459	01.11.01	Ravetch, J.			
	166	2003/0166868	04.09.03	Presta et al.			
	167	2004/0191244A1	30.09.04	Presta, L.			
	168	2004/0228856A1	18.11.04	Presta, L.			
	169	4,490,473	25.12.84	Brunhouse			
	170	5,419,904	30.05.95	Irie, R.			
	171	5,731,168	24.03.98	Carter et al.			
	172	6,676,927	13.01.04	Ravetch, J.			
	173	6,737,056	18.05.04	Presta, L.			
	174	6,821,505	23.11.04	Ward, E.			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	175	Antibodies. A Laboratory Manual, Harlow and Lane, New York: Cold Spring Harbor Laboratory pps. 321 (1988)
	176	Fridman, W., "Fc receptors and immunoglobulin binding factors" <u>FASEB Journal</u> 5(12):2684-2690 (Sep 1991)
	177	Fundamental Immunology, Paul, W. E., 2nd edition, New York: Raven Press pps. 60 and 61 (1989)
	178	Kim et al., "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn" <u>European Journal of Immunology</u> 29(9):2819-2825 (Sep 1999)
	179	Male, D. <u>Immunology, An Illustrated Outline</u> , London: Gower Medical Publishing Ltd. pps. 21 and 23 (1986)
	180	Martin et al., "Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding" <u>Molecular Cell</u> 7(4):867-877 (Apr 2001)
	181	Newkirk et al., "Rheumatoid factor avidity in patients with rheumatoid arthritis: identification of pathogenic RFs which correlate with disease parameters and with the gal(0) glycoform of IgG" <u>Journal of Clinical Immunology</u> 15(5):250-257 (Sep 1995)
	182	Williams et al., "Heteroclitic polyclonal and monoclonal anti-Gm(a) and anti-Gm(g) human rheumatoid factors react with epitopes induced in Gm(a-), Gm(g-) IgG by interaction with antigen or by nonspecific aggregation" <u>Journal of Immunology</u> 149(5):1817-1824 (Sep 1, 1992)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.